346 related articles for article (PubMed ID: 9112654)
21. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
[TBL] [Abstract][Full Text] [Related]
22. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
[TBL] [Abstract][Full Text] [Related]
23. Plasminogen activators and inhibitor type-1 in alveolar osteitis.
Serratì S; Margheri F; Bruschi S; D'Alessio S; Pucci M; Fibbi G; Tonelli P; Del Rosso M
Eur J Oral Sci; 2006 Dec; 114(6):500-3. PubMed ID: 17184232
[TBL] [Abstract][Full Text] [Related]
24. Protein C and its inhibitor in malignancy.
Suzuki K; Hayashi T
Semin Thromb Hemost; 2007 Oct; 33(7):667-72. PubMed ID: 18000793
[TBL] [Abstract][Full Text] [Related]
25. Changes in pericardial morphology and fibrinolytic activity during cardiopulmonary bypass.
Nkere UU; Whawell SA; Thompson EM; Thompson JN; Taylor KM
J Thorac Cardiovasc Surg; 1993 Aug; 106(2):339-45. PubMed ID: 8341074
[TBL] [Abstract][Full Text] [Related]
26. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
27. Effects of N-(4-hydroxyphenyl) retinamide on urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in prostate adenocarcinoma cell lines.
Tanabe T
Hiroshima J Med Sci; 2000 Mar; 49(1):67-72. PubMed ID: 10824459
[TBL] [Abstract][Full Text] [Related]
28. Expression of tissue type and urokinase type plasminogen activators as well as plasminogen activator inhibitor type-1 and type-2 in human and rhesus monkey placenta.
Hu ZY; Liu YX; Liu K; Byrne S; Ny T; Feng Q; Ockleford CD
J Anat; 1999 Feb; 194 ( Pt 2)(Pt 2):183-95. PubMed ID: 10337950
[TBL] [Abstract][Full Text] [Related]
29. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot AJ; van Tienoven DT; Beex LV; Sweep FC
Thromb Haemost; 2004 Mar; 91(3):514-21. PubMed ID: 14983227
[TBL] [Abstract][Full Text] [Related]
30. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
31. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
32. Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer.
Steiner E; Pollow K; Hasenclever D; Schormann W; Hermes M; Schmidt M; Puhl A; Brulport M; Bauer A; Petry IB; Koelbl H; Hengstler JG
Gynecol Oncol; 2008 Mar; 108(3):569-76. PubMed ID: 18222533
[TBL] [Abstract][Full Text] [Related]
33. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ
Cancer Res; 2000 Oct; 60(20):5839-47. PubMed ID: 11059781
[TBL] [Abstract][Full Text] [Related]
34. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR
J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981
[TBL] [Abstract][Full Text] [Related]
35. Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
Boss EA; Massuger LF; Thomas CM; Geurts-Moespot A; van Schaik JH; Boonstra H; Sweep CG
Anticancer Res; 2002; 22(1A):275-82. PubMed ID: 12017303
[TBL] [Abstract][Full Text] [Related]
36. Blood urokinase plasminogen activator system in chronic urticaria.
Kasperska-Zajac A; Brzoza Z; Rogala B
Arch Dermatol Res; 2007 Jan; 298(8):409-11. PubMed ID: 17102952
[TBL] [Abstract][Full Text] [Related]
37. Peritoneal fibrinolytic response to various aspects of laparoscopic surgery: a randomized trial.
Brokelman WJ; Holmdahl L; Bergström M; Falk P; Klinkenbijl JH; Reijnen MM
J Surg Res; 2006 Dec; 136(2):309-13. PubMed ID: 17054995
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of Borrelia burgdorferi-bound fibrinolytic enzymes by alpha2-antiplasmin, PAI-1 and PAI-2.
Perides G; Noring R; Klempner MS
Biochem Biophys Res Commun; 1996 Feb; 219(3):690-5. PubMed ID: 8645243
[TBL] [Abstract][Full Text] [Related]
39. Progestin inhibits and thrombin stimulates the plasminogen activator/inhibitor system in term decidual stromal cells: implications for parturition.
Norwitz ER; Snegovskikh V; Schatz F; Foyouzi N; Rahman M; Buchwalder L; Lee HJ; Funai EF; Buhimschi CS; Buhimschi IA; Lockwood CJ
Am J Obstet Gynecol; 2007 Apr; 196(4):382.e1-8. PubMed ID: 17403427
[TBL] [Abstract][Full Text] [Related]
40. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
Morii T; Yabe H; Morioka H; Yamada R; Nakagawa T; Toyama Y
Anticancer Res; 2000; 20(5A):3031-6. PubMed ID: 11062719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
